Conference Coverage

General images of ESMO 2019 Congress being held in Barcelona, Spain, September 27 - October 1, 2019. Courtesy European Society for Medical Oncology (ESMO). Used with Permission.

Phase I/IIa Trial Evaluating BT1718 Shows Encouraging Progress in Dose Escalation Phase

Updated data from a Phase I/IIa trial evaluating BT1718, a Bicycle Toxin Conjugate being developed Bicycle Therapeutics, was presented...
General images of ESMO 2019 Congress being held in Barcelona, Spain, September 27 - October 1, 2019. Courtesy European Society for Medical Oncology (ESMO). Used with Permission.

ESMO 2019: FORWARD I Study of Mirvetuximab Soravtansine in Ovarian Cancer Did Not Meet...

The full data and exploratory analyses from the Phase III FORWARD I study (NCT02631876) evaluating mirvetuximab soravtansine, also known...
General images of ESMO 2019 Congress being held in Barcelona, Spain, September 27 - October 1, 2019. Courtesy European Society for Medical Oncology (ESMO). Used with Permission.

ESMO 2019: Combination of Enfortumab Vedotin + Pembrolizumab Shows High ORR in Urothelial Cancer

Initial results from EV-103, a phase I clinical trial (NCT03288545) of the investigational antibody-drug conjugate enfortumab vedotin (also known...
Featured Image: Annual Congress of ESMO 2018. Courtesy: © 2018 European Society for Medical Oncology. Used with permission.

ESMO 2019: Seattle Genetics to Present Initial Data from a Phase I Trial Results...

Less than a week before the start of the annual meeting of the European Society for Medical Oncology (ESMO),...

Dose Escalation Shows DS-1062 to be Well-tolerated with Partial, Dose-dependent, Responses

Results of a Phase I clinical study and new biomarker data for DS-1062 in 52 unselected patients...

Late-breaking Results: HER3 Targeting U3-1402 in Patients with Metastatic EGFR Mutated, TKI Resistant NSCLC...

Updated phase I data for U3-1402, an investigational HER3 targeting antibody-drug conjugate or ADC being developed by...

WCLC 2019: Daiichi Sankyo to Present Late-breaking Results from U3-1402 and DS-1062 Studies

The World Health Organization (WHO) estimates that lung cancer causes 1.59 million deaths globally per year. Non-small cell lung...
East Village, San Diego. Photo by Derek Story on Unsplash

Conference Update – 10th Annual World ADC San Diego 2019

With the recent accelerated approval from the FDA for Genentech’s Polivy for patients with relapsed or refractory diffuse large...
Featured Image: Close-up cityscape of Lugano city waterfront along Lugano Lake. Facades of historic houses in front of alp mountains. Courtesy: © 2017. Fotolia. Used with permission.

15th ICML: Camidanlumab Tesirine Shows High Overall Response Rate in R/R Classical Hodgkin Lymphoma

During the International Conference on Malignant Lymphoma (ICML), one of the must-attend events for the scientific community involved in...

15th ICML: Loncastuximab Tesirine Shows Significant Activity in R/R Diffuse Large B-cell Lymphoma

Loncastuximab tesirine (ADCT‐402), an anti‐CD19 antibody‐drug conjugate (ADC) conjugated via a protease cleavable linker to SG3199, a highly cytotoxic...